Melbourne Health

Artugen Therapeutics Ltd.

Bacainn Biotherapeutics, Ltd.

Clearb Therapeutics Ltd.

Ronald Farquhar

Stephen Locarnini

Paul Ross

Colin Hill

Chris Murphy

Mary Rea

Laurent Chesnel

Christopher K Murphy

Hans Netter

Renae Walsh

Michelle O'Donnell

Roland E Dolle

Brian Healy

Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPRL.

Cyclosporine compositions and methods of use

Disclosed herein are cyclosporine compounds and methods for use in the treatment or prevention of neutrophil-mediated inflammation, wherein the compounds inhibit the activity of MRP2 and FPR1.

Disclosed herein are compositions and methods for the treatment of hepatitis B infection, including chronic hepatitis B (CHB).

Methods and compositions for the treatment of hepatitis B infection

Disclosed herein are compositions and methods for preventing, ameliorating, or treatinginfections and/or reducing the severity of one or more risk factors, signs, or symptoms associated withinfections. In particular, the technology of the present disclosure relates to methods for administering an effective amount of a composition comprising strains ofbacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk forinfections.

Methods and compositions for the treatment of C. difficile

Disclosed herein are compositions and methods for preventing, ameliorating, or treatinginfections and/or reducing the severity of one or more risk factors, signs, or symptoms associated withbacteria identified as ART24, ART4, and ART 12, to a subject suffering from or at risk forinfections.

Growing community of inventors

Boston, MA, United States of America

Ronald Farquhar